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(1)
DIFFERENT APPLICATIONS FOR 
GENETICALLY MODIFIED CROPS 
WEDNESDAY, JUNE 29, 2005
HOUSE OF REPRESENTATIVES 
SUBCOMMITTEE ON RURAL ENTERPRISES, AGRICULTURE 
AND TECHNOLOGY 
COMMITTEE ON SMALL BUSINESS 
Washington, DC 
The Subcommittee met, pursuant to call, at 2:04 p.m. in Room 
311, Cannon House Office Building, Hon. Sam Graves presiding. 
Present: Representatives Graves, Sodrel, Barrow, Udall, Case
Mr. GRAVES. We will go ahead and call this hearing to order. We 
have kind of got a little dilemma here. We have got to vote at any 
second now. It was supposed to be about 10 minutes ago, and obvi-
ously it has been delayed, for whatever reason, but I think we are 
going to go ahead and proceed forward. We can get some of the 
opening statements taken care of by some of the Members and 
move forward from there. 
But I would like to welcome everybody to the Rural Enterprises, 
Agriculture and Technology Subcommittee, part of the overall 
Small Business Committee, and today we are going to be looking 
at different applications for genetically modified crops. Again, I 
want to thank everybody here today, our audience, and those who 
are participating in the hearing. Some of you have come from a 
long ways, and I appreciate you coming out to testify today. 
As a farmer by trade myself, I truly believe genetically modified 
crops are the future of American agriculture. As agriculture mar-
kets become more competitive worldwide, it is imperative that the 
United States keep an edge by offering continued superior quality 
product. Genetically modified crops allow agribusiness to increase 
profits and continue to uphold the United States’ representation for 
excellence in agriculture. 
For centuries, farmers have been modifying crops to improve 
their growth rates and yields. We have seen technology, not only 
improve these yields, but also to create varieties resistant to pests 
and diseases. Such modifications have previously been made 
through cross-breeding plants with desirable traits and through hy-
bridization. Thomas Jefferson himself was renowned for his work 
in cross-pollination and hybridization at Monticello. 
Already in this country, 85 percent of all of the soybeans we grow 
have been modified, followed closely by 75 percent of all of the cot-
ton and half of the corn. Thirteen different plants in the U.S. today 
have been approved to be genetically modified, and, in fact, some 
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260 percent of all of the food that we grow and consume is geneti-
cally modified. Continued developments and research hold great 
promise for traditional agriculture not only when it comes to feed-
ing the world but also to produce crops for medical purposes. 
Through advanced technology, scientists can modify specific 
genes for desired qualities and grow them within the plants. Com-
monly referred to as ‘‘biofarming,’’ this method of retrieving certain 
enzymes holds limitless potential and will allow the United States 
to retain its leadership role within the medical research commu-
nity. 
Worldwide, genetically modified crops offer hope, incredible hope, 
as a matter of fact, for overpopulated countries when it comes to 
feeding and treating the people in a much more efficient and a 
much more effective way. I am greatly concerned that current regu-
lations and a lack of knowledge for this science will not only ham-
per growth in this industry but will also allow other countries to 
surpass the United States’ position as a world leader within the ag-
riculture business industry. 
We have to continue to make policy decisions based on sound, 
scientific facts and help businesses to expand in this industry. I 
think we have a great potential to not only revitalize rural busi-
ness communities but also offer an incredible product to consumers 
throughout the United States and throughout the world. 
Again, I am looking forward to hearing what all of the witnesses 
have to say—this is going to be a great hearing to talk about the 
great things when it comes to genetically modified crops—and 
learning more about this expanding industry. I am pleased to rec-
ognize now Ranking Member Barrow for his opening statement, 
and good to have you. 
[Chairman Graves’ opening statement may be found in the ap-
pendix.] 
Mr. BARROW. Thank you, Mr. Chairman. Mr. Chairman, the agri-
cultural sector has always played a central role in the success of 
the United States economy, and as the representative for Georgia’s 
12th District, I know how important agricultural interests are not 
only to my area of the country but to the entire country, and it is 
important for us to remember that farming and rural communities 
are a critical component of the history and landscape of our nation. 
Generations of Americans have relied on the strength of our agri-
culture through the hard work, dedication, and innovation of our 
farmers. 
The importance of the agriculture and farming industries has 
continued to evolve with the growth of our nation. From early 
farming techniques, such as crop rotation and irrigation systems, 
to 19th century inventions, such as the steel plow and the cotton 
gin, farmers have always looked for ways to increase productivity 
and maximize crop yields. 
Today, small family farms and other agriculture-related busi-
nesses help to meet our needs and contribute to local and national 
economies. With farmers having such a strong presence in my dis-
trict, I know how important their success is to economic develop-
ment. In Georgia, agriculture is our largest industry, contributing 
over $57 billion, or 16 percent of the state’s $350 billion annual 
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3economic output. In fact, in many parts of my district, the farm 
economy is the economy. 
As we make our way through the early years of this century, bio-
technology and genetic engineering our some of the advances lead-
ing the way in agriculture innovation. These methods may hold the 
promise to ensure the continued success of the farming industry, 
even as we face increased demands and especially as fewer people 
in each generation turn to farming as a profession. High-technology 
applications and improved crop yields are extremely important to 
the U.S. agricultural economy and the rural economy because they 
will help us meet the challenges facing the small farmer and re-
duce the risk to crops and the land itself. 
Today’s hearing will give us an opportunity to learn more about 
genetically engineered crops and the scientific gains that are lead-
ing us in this direction. It will also provide an overview to the bar-
riers that we face in bringing this science on line in the face of re-
sistance around the world. This is an instance, Mr. Chairman, 
where scientists, businesses, and farmers need to work together to 
grow their own future. 
Genetically engineered crops were first introduced in 1996 for 
commercial production. They are now planted on 167 million acres 
of farm land around the world. Of this, the U.S. accounts for nearly 
two-thirds of all biotechnology crops planted worldwide, including 
soybeans, cotton, corn, canola, tomatoes, potatoes, papaya, and 
squash. According to the Biotechnology Industry Organization 
group, 70 percent of all processed foods on our shelves today con-
tain products enhanced by biotechnology. By selecting specific 
genes from one organism and transferring these desired traits to 
another, scientists have been able to produce new varieties that are 
stronger, more resistant, and better equipped to handle harsh 
weather conditions and withstand insects and other pests. Amer-
ican farmers, large and small, have been able to take advantage of 
our technology agriculture, and that is what is keeping the U.S. the 
world’s leader in the field. 
This is an important hearing for the folks you represent, Mr. 
Chairman, and for mine. For farmers in Georgia and across the na-
tion, it is important to hear what to expect in the future in terms 
of research and production of genetically engineered crops. 
I look forward to hearing all of the testimony of today’s wit-
nesses, particularly Tommy Dollar, a Georgia farmer who is the 
president and owner of Dollar Farm Products and the Decatur Gin 
Company. Thank you, Mr. Chairman. 
Mr. GRAVES. Thank you, Mr. Barrow. 
Mr. Udall? 
Mr. UDALL. I do not have anything, Mr. Chairman. I look for-
ward to hearing from the witnesses. Thank you very much. 
Mr. GRAVES. Mr. Case? 
All right. We will move forward, then, and it looks like we had 
a vote through voice vote. It is not going to be recorded, so that is 
good news. We can continue forward. I do want to make it clear 
that all of the statements made by the witnesses and the members 
will be placed in the record in their entirety. Also in front of you, 
you will notice that you have a little box. It is green. I think every-
body has five minutes, and then it goes to yellow with one minute 
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4left, and it is red after that. Do not worry about it. If you have got 
something to say, I want to hear it, and do not pay too much atten-
tion to it. It is just, for the most part, to keep us on track and mov-
ing forward, so if it turns red, do not be too alarmed. 
We are going to start, and what I am going to do is I will intro-
duce you as we move through. I will let everybody give an opening 
statement, and then we will come back through with the questions. 
First off, we have got Sam Huttenbauer, who is the CEO of 
Agragen in Cincinnati, Ohio. We have actually got both Sams here, 
senior and junior, I assume. I am a junior, so I understand how 
that is. We are looking forward to hearing your testimony, and 
please go ahead. 
STATEMENT OF SAM HUTTENBAUER, AGRAGEN 
Mr. HUTTENBAUER. Good afternoon, Mr. Chairman and members 
of the Committee. Thank you for giving me the opportunity to par-
ticipate in this panel. 
My name is Sam Huttenbauer, and I am the president of 
Agragen, Inc., a biotech company working on the development of 
plant-made pharmaceuticals, otherwise known as ‘‘PMPs.’’ We are 
located in Cincinnati, Ohio, and are opening up a laboratory facility 
in Grand Forks, North Dakota, where we plan to grow and process 
our pharmaceuticals. 
I am pleased to testify today at this hearing regarding the future 
potential of PMPs and their tacit economic impact towards bol-
stering America’s agricultural economy. 
Agragen was started three year ago with the express purpose of 
manufacturing pharmaceuticals utilizing the natural protein-manu-
facturing capability of plants. The company has also concentrated 
since its inception on selecting molecular targets that require sub-
stantial agricultural acreage. Agragen is one of the new breed of 
agribusiness companies combining conventional agriculture with 
high-tech science. As such, it will work with farmers, employing 
their agronomic expertise and existent land. With America’s agri-
culture undergoing change in the competitive world arena, Agragen 
and companies like it present one opportunity to move our coun-
try’s great food-and-fiber skills into a more profitable and stable 
system. 
Plant-made pharmaceuticals are the new, ultra-high-value farm-
ing for the 21s century. What are ‘‘plant-made pharmaceuticals?’’ 
PMPs are the result of the breakthrough application of bio-
technology to plants to enable them to produce therapeutic proteins 
that will be used by the medical community to combat life-threat-
ening illnesses. In this process, plants themselves become factories 
that manufacture therapeutic proteins. These proteins are then ex-
tracted, refined, and used in pharmaceutical production. These 
plants are grown under highly regulated conditions in defined 
growing environments and are strictly regulated by the U.S. De-
partment of Agricultural, its animal and plant health inspection 
service, and by the Food and Drug Administration. 
Why do we want to use PMPs? Well, as the world’s scientific 
technology increases, more and more drug therapies rely on recom-
binant proteins and less on traditional combinatorial chemistry. 
While this represents monumental breakthroughs in healing, it 
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5also presents significant problems of economics, efficiency, and 
safety. Consider this: Over 14 percent of treatments in clinical 
trials today require recombinant proteins. It takes five to seven 
years to build a biotech plant capable of producing recombinant 
proteins versus one to three years for a conventional pharma-
ceutical plant. And just four molecules currently consume 75 per-
cent of the existing capacity to make recombinant proteins. Over 
100 new, protein-based medicines are now in late-stage clinical 
trials. 
There are also many challenges to current recombinant produc-
tion methodologies. From an economic standpoint, current biotech 
plants require five to seven years to construct, cost 250 to $450 
million, and must be individually approved and certified by the 
FDA prior to full-scale operation. From a supply standpoint, de-
spite increased therapeutic use of recombinant proteins, there is a 
global shortage of production facilities, less than 12 worldwide for 
these new proteins. This greatly limits the movement of these pro-
teins into therapeutic use, and from a safety standpoint, there is 
the possibility of cross-contamination with human or mammalian 
contaminants utilizing the current production methodologies. 
Plants provide a number of advantages over other production 
methods of biomedical materials. Cost, for instance. Plant vaccines 
and proteins are inexpensive to produce relative to the cost of tra-
ditional vaccines and proteins. 
From a safety standpoint, the use of plants for the production of 
biomedical materials eliminates the possibility of cross-contamina-
tion with human and animal pathogens. 
From an economic standpoint, farming is already an important 
and established part of our global economy, and from a practicality 
and flexibility standpoint, because one plant can express several 
antigens simultaneously, vaccines against a variety of pathogens 
can be produced in a single plant. In addition, plants producing 
therapeutics can be rapidly scaled up as demand increases simply 
by planting more acres. 
The industry needs a cheaper, more effective way to manufacture 
today’s and tomorrow’s pharmaceuticals. PMPs offer this alter-
native. Plants approved for the use of biotechnology can produce 
the essential building blocks or therapeutic proteins for innovative 
treatments for diseases such as Alzheimer’s; cancer; chronic, ob-
structive pulmonary disease; Crohn’s disease; cystic fibrosis; diabe-
tes, and many others at a fraction of the cost of current manufac-
turing methods. 
Agragen is not currently what might be classified as a drug-dis-
covery company, having chosen to focus on established therapeutics 
that are market limited, either due to extreme production costs or 
limited production capacity. Once we have established our produc-
tion platform, this will lead to additional pharmaceuticals that will 
also require large acreage. The overall thrust of our technology is 
to insert genes into the plant, thereby permitting the plant to make 
and store the protein of interest in the seed where it can be stored 
indefinitely until it is purified. 
From a business standpoint, plant-made pharmaceuticals rep-
resent a means to reduce the production costs and to increase the 
availability of many new drug therapies with the downstream ef-
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6fect of dramatically reducing costs to consumers and allowing life-
saving therapies to find their way into the hands of many patients 
who would not have access, either due to cost or availability. 
Agragen has selected two products for the initial stages of pro-
duction and several additional candidate proteins. These initial 
products are in line with the company’s goals, which are the utili-
zation of a large amount of acreage and the passing of value-added 
agricultural profits back to the farmers, for three reasons. 
First, both represent $1 billion-plus, underserved and growing 
markets; second, both targets will ultimately require large acreage, 
in the neighborhood of 100,000 acres-plus, and spawn meaningful 
infrastructure in the areas where they are developed; and, third, 
both molecules are currently being utilized in the marketplace, 
which will reduce both clinical test costs and time to market. As 
recombinant-protein science becomes an increasingly important 
technique for the formation of new therapeutics, manufacturing ca-
pabilities must keep pace. 
Agragen is one of a number of companies that understands the 
capabilities and cost efficiency of plants serving as pharmaceutical 
factories. In addition, plants offer genetic mechanisms that may 
allow discovery and creation of molecules that cannot be con-
structed from any other source. 
To be truly beneficial for small rural business, plant-made phar-
maceuticals must be tied to open-field production. PMPs utilizing 
plants created in laboratories or in greenhouses have little or no 
connection to the agribusiness system. While these operations can 
utilize plants’ natural production mechanisms to produce life-sav-
ing therapeutics, they do not provide an opportunity for the Amer-
ican farmer. 
Large PMP farms, similar to what Agragen is creating, can be 
established around the country utilizing a large number of acres, 
either supplementing lost state farming acreage or establishing 
new growth. In many cases, there will be the opportunity for both. 
Farmers benefit from the production of PMP-producing crops via 
their provision of steady employment of their fields and by their 
greater cash-to-crop yield than is available via the current agricul-
tural industry. 
In addition to supplying farmers with a new, high-value crop, 
Agragen envisions further rural economic involvement by potential 
farmer ownership of PMP processing and manufacturing facilities. 
Agragen’s business model offers farmers and rural economies the 
opportunity to participate firsthand in this new, value-added family 
of crops. The goal of this novel form of agribusiness is to bring the 
farmer into the process of partner, which specifically means allow-
ing operators to share in the profitability of what they are manu-
facturing. 
Agragen believes that it can double or possibly triple the bottom 
line of its partners with a market price that is far more stable than 
typical focused commodities. Furthermore, Agragen’s impact will be 
felt in equipment sales, transportation and processing jobs, real es-
tate values, et cetera. Facilities to handle the transformation of the 
large biomass from field crop to pharmaceutical will have to be lo-
cated within proximity to actual growing areas. This means mil-
lions of dollars in construction and additional opportunities for 
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7skilled employees in rural locations. Our own initial projections 
allow—our first two output products show close to $80 million in-
fused in the economy of the state that we will operate in. 
We see an instant opportunity to utilize American agronomic 
skills to help replace some farm products that might be rendered 
marginal by rapidly developing worldwide agricultural production. 
PMPs offer the possibility for the small farmer businessman to 
share in a potentially large profit market while providing tangen-
tial benefits to rural economies that would not be subject to new 
investment otherwise. 
However, being immersed in the standard farming arena is not 
without its problems. Typical agricultural challenges, such as 
weather and parasites, can be mitigated by the use of multiple 
growing regions and protein development in seeds which allow for 
long-term storage and thus the capability to stockpile. But the 
greatest immediate threat comes from public perception. Field pro-
duction pits PMP companies against GM antagonists, organic farm-
ers, particularly those who may have an interest in the crop species 
being transformed. 
There has been a call for all PMP crops to exclude any plants 
currently used for food or feed. Unfortunately, while many plants 
possess the potential for protein production, certain species are bet-
ter matched with specific targeted proteins. Some plants may serve 
as excellent converters, i.e., tobacco, but require too high economic 
inputs or extraordinarily expensive processing procedures. The 
need to utilize the production capacity of food crops will be nec-
essary, but these crops are solely used as a factor and will never 
enter the food chain. 
Unlike former GM plant transformations, including the now-no-
torious Starling corn, where crops basically enter a side-by-side 
handling and distribution system and one where the possibility of 
interchange with non-GM materials is always present, PMPs will 
never have the opportunity to mix with their commodity counter-
parts. PMPs must adhere to a close-loop system that will include 
dedicated equipment, transportation, storage, processing, and 
waste handling. 
Still, public perception issues exist. Chief among them is the fear 
that PMP crops will contaminate non-PMP fields vis-a-vis pollen 
drift. This is not an insurmountable issue. A major step forward oc-
curred recently in Missouri where government officials played a 
large role in resolving a similar PMP-related controversy. In Mis-
souri, the problem was untangled by diverse separation, essentially 
using large distances to keep PMP crops away from that being pro-
duced for the food system. 
Distance is an effective means to mitigate crop commingling; 
however, it might not always be enough. In addition to distance re-
quirements, the USDA mandates that all PMPs must be grown 
using a tight, closed-loop system with dedicated equipment, ship-
ping trucks, and plant material and pollen to prevent them from 
mixing. 
In Agragen’s case, because of the ultimate magnitude of the acres 
projected, the solution might only be temporary. Other methods are 
being developed to take a more proactive approach to containing 
the PMP agriculture. For example, Agragen is hard at work devel-
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8oping novel, gene-control mechanisms that will make mixing with 
other plants a statistical improbability. 
In conclusion, Mr. Chairman, I want to reiterate that by working 
with established control mechanisms under the guidance of the 
USDA and other organizations, by working with state and local of-
ficials, and by incorporating the knowledge of the farmers them-
selves, PMPs can be safely grown throughout the states. 
According to a report by a consultancy, Frost & Sullivan, re-
leased in December 2004, the U.S. market for plant-made pharma-
ceuticals could be worth $2.2 billion by 2011, with the first prod-
ucts reaching the market by 2005-2006. Agragen believes that from 
that point, its growth will be restrained only by discovery science 
not keeping pace. This can translate into direct economic growth 
for U.S. agriculture as companies utilize more and more acres for 
PMP production. 
PMPs offer not only the promise of cheaper, more abundant 
pharmaceuticals but the establishment of a new, ultra-high-agricul-
tural venue for today and tomorrow’s farmer. Agragen, by bringing 
the farm community into its business system, feels that it will eco-
nomically benefit rural areas and individuals who otherwise would 
have no connection to the biotech revolution. Thank you, Mr. 
Chairman. 
[Mr. Huttenbauer’s testimony may be found in the appendix.] 
Mr. GRAVES. Thank you. Next, we are going to hear from Dawn 
Parks. Dawn is public, industry, and government affairs manager 
for ArborGen in Summerville, South Carolina. Did I get that right? 
Ms. PARKS. Yes, you did. Thank you. 
Mr. GRAVES. I look forward to hearing what you have to say. 
STATEMENT OF DAWN W. PARKS, ARBORGEN 
Ms. PARKS. Thank you. Good afternoon, Mr. Chairman, members 
of the Committee, ladies and gentlemen. I am Dawn Parks. I am 
the director of public and government affairs for ArborGen. 
I am privileged to be here this afternoon on behalf of ArborGen, 
as well as on behalf of our trade organization, the Biotechnology 
Industry Organization. BIO represents more than 1,100 companies, 
academic institutions, state biotech centers, and related organiza-
tions across the United States and in 31 other nations. BIO mem-
bers are actively involved in the research and development of new 
medicines, food, and industrial and environmental products to ben-
efit the lives of people and the environment. 
I would like to thank Chairman Graves and members of the 
Committee for the opportunity to be with you today and for orga-
nizing this hearing. I would also like to thank you, Mr. Chairman, 
for your leadership on the Small Business Innovation Research pro-
gram. Specifically, I want to take this opportunity to publicly ex-
press BIO’s and BIO’s member companies’ appreciation for your in-
troduction of H.R. 2943, the Save Biotechnology Innovative Re-
search Act of 2005. This important legislation preserves venture 
capital-backed biotechnology small businesses’ access to vital Small 
Business Administration grants. 
In this tenth year of growing crops enhanced through bio-
technology, global acceptance continues to increase at a rapid pace. 
According to the International Service for the Acquisition of Agr-
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9Biotech Applications, in 2004, global biotech crop plantings contin-
ued to grow at a sustained double-digit rate of 20 percent, com-
pared with 15 percent in 2003. The estimated global area of ap-
proved crop plantings was more than 200 million acres in 2004. 
The United States is the world leader in the development and 
planting of these crops, and rural America is one of the chief bene-
ficiaries. In 2004, American farmers chose to plant 85 percent of 
the soybeans, 76 percent of cotton, and 45 percent of corn with 
seeds improved through biotechnology that allow the plants to pro-
tect themselves from insects and disease and promote better weed 
management. The United States has also approved for commercial 
planting biotech varieties of canola, chicory, flax and linseed, 
melon, papaya, potatoes, rice, squash, sugar beets, tobacco, and to-
mato. The annual R&D investment of the six largest companies in 
this sector is $2.7 billion, or 10.8 percent of sales. 
The rapid adoption of this technology by U.S. farmers is a testa-
ment to the solutions it provides to problems on the farm. Bio-
technology enables farmers to reduce input costs and improve 
yields. 
My company, ArborGen, is a small business, but the research 
and development we are doing at our headquarters in Summerville, 
South Carolina, holds potential to improve forestry on a national 
and international scale. Forestry, of course, is a rural business that 
supports millions of jobs across America. 
Our goal at ArborGen is to use breeding techniques, including 
biotechnology, to improve the sustainability of forestry. According 
to the Food and Agriculture Organization, about one-third of the 
harvested wood is supplied from industry-owned, highly managed 
tree plantations. The rest comes from landowners that utilize a 
wide variety of management techniques, including natural forest 
management. 
As the worldwide population increases, so does the demand for 
wood and paper products. Rather than expanding the forested acre-
age under management to meet these wood and paper require-
ments in the future, we are developing faster-growing trees that 
will improve the productivity of forest plantations, and by pro-
ducing more wood on less land, people can build the homes and buy 
the products they desire without cutting down our natural forests, 
which will be conserved for wildlife, recreation, biodiversity, and 
beauty. 
ArborGen also is developing trees with modified lignin. Lignin is 
a component of wood fibers that is removed during the pulping 
process to obtain the cellulose needed to make paper. The process 
involves intensive use of chemicals and energies. Reducing lignin 
content in the trees intended for pulp, or by making it easier to re-
move the lignin during the manufacturing process, will provide im-
portant environmental benefits. 
The area of forestry biotechnology has potential to bring many 
other benefits, and several institutions around the world are devel-
oping really exciting products that have significant social, environ-
mental, and economic benefits. One key potential benefit is the pro-
duction of cleaner burning fuels. Wood produced for ethanol or used 
directly as fuel by power companies would be a clean, renewable, 
and cost-effective energy resource. 
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Phyto-remediation of Superfund sites or other toxic lands is an-
other very promising possibility. Instead of spending billions of dol-
lars removing and sterilizing impaired soils, it may be feasible to 
plant modified trees that can absorb and neutralize hazard wastes 
and heavy metals. 
Biotechnology can also help restore endangered species, such as 
the American chestnut, American elm, flowering dogwood, and the 
California oaks. A single disease-resistance gene added to chestnut 
could allow for these beautiful species to withstand the blights that 
have nearly obliterated them from the landscape. Field trials with 
American elm are underway now, and chestnut trials should begin 
soon. 
Another possibility is trees that can grow in harsh conditions, 
such as arid climates or salty soils. In areas where trees are an im-
portant part of the landscape, this technology could halt further en-
croachment of the desert and allow trees to grow in areas where 
they are now unable to grow. And the ability to grow important 
hardwoods more quickly on managed lands could halt the black 
market harvesting of these species in natural forests. 
Forest biotechnology is in its infancy, but it holds unlimited pos-
sibilities that would take generations to produce through tradi-
tional cross-breeding. Instead of waiting for trees to grow to sexual 
maturity so they can be cross-bred with one another, forest bio-
technology can identify a desirable gene and transfer it to a tree. 
The success of failure of the transfer can be seen almost imme-
diately. Then through high-production, multiplication systems, we 
can mass produce plantlets and introduce large numbers of the im-
proved trees to supply plantation foresters so they can begin to pro-
vide benefits to this generation of citizens and into the future. Per-
haps adults living today will be able to stand beneath the shade 
of a spreading chestnut tree, just as their great-grandparents did. 
Mr. Chairman, I hope you can understand from my testimony 
how excited I am to be part of this emerging industry. There are, 
however, threats to the continued success of the research I have 
just described, the most daunting being the exclusion of companies 
such as ArborGen, with majority private funding from companies, 
from participating in SBIR programs. 
While BIO does represent companies in the industry, the vast 
majority of its members, over 85 percent, are small, emerging com-
panies with less than 500 employees. In fact, more than 50 percent 
of the companies in our industry have fewer than 50 employees. In 
our case, a company with 70 employees, it strikes us as unthink-
able that we would be considered ineligible for an SBIR grant be-
cause we receive private funding for our core projects. 
Under the current interpretation of the eligibility, we are con-
cerned ineligible because, as a start-up company, we did what vir-
tually all early stage start-up companies do to continue their re-
search: We received funding for early research and development 
projects from corporate investors. Funding partners often support 
the development of the critical platforms, technologies, and proto-
cols that will lead to products for a particular kind of industry. 
But, for example, as we develop products designed for improving 
forest management and manufacturing efficiencies, we have identi-
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fied genes that can provide significant values to industries outside 
of paper making and lumber. 
The SBIR program is ideally suited for this purpose because the 
company, our company, has already demonstrated that it can suc-
cessfully raise follow-on financing, one of the key criteria in evalu-
ating an SBIR Phase II grant proposal. 
To remove this barrier to participation in the SBIR program, BIO 
has urged SBA to revise the SBIR eligibility requirements and 
issue a proposed rule that reflects Congress’s original intent to en-
courage awards to small businesses that have successfully at-
tracted outside investors. 
The approach proposed by SBA in its December 3, 2004, ad-
vanced notice of proposed rulemaking to disregard affiliation is a 
step in the right direction. However, it does not address the funda-
mental obstacle, which is SBA’s requirement that small businesses 
be majority owned and controlled, directly or indirectly, by individ-
uals. The SABIR Act, however, clarifies that biotechnology small 
businesses receiving venture capital funding are, in fact, eligible for 
SBIR Phase II grants. We thank you so much, Mr. Chairman, for 
your leadership on this very important issue. 
Mr. Chairman, we appreciate your leadership on these issues 
and look forward to continuing to work towards a resolution. 
Thank you for giving me the opportunity to provide this informa-
tion to you today. I look forward to answering any questions that 
you may have. 
[Ms. Parks’ testimony may be found in the appendix.] 
Mr. GRAVES. Thank you, Ms. Parks, and thank you for men-
tioning the venture capital issue that we have got up. I actually 
testified on that yesterday in another Committee, and we are going 
to have a hearing on it in this Committee in about a month. So we 
might ask you for your input on that, too. 
I will let Mr. Barrow introduce our next witness. 
Mr. BARROW. Thank you, Mr. Chairman. I am pleased to intro-
duce to the Committee Mr. Thomas Dollar. Mr. Dollar is a third-
generation Georgia farmer. In addition to growing over 3,000 acres 
of cotton and peanuts, he is the president of both the Decatur Gin 
Company and the Miller County Gin Company. Both businesses gin 
about 56,000 acres of cotton each year. 
Mr. Dollar sells materials and supplies to farmers. He is a grow-
er and crop producer, and he is a crop processor as well. He is here 
to talk about the impact that agricultural genetic engineering is 
having on agriculture in my part of the country. 
Mr. Dollar, thank you for being here today. 
STATEMENT OF THOMAS H. DOLLAR, II, DOLLAR FARM 
PRODUCTS COMPANY, DECATUR GIN COMPANY 
Mr. DOLLAR. Thank you very much. Thank you, Chairman 
Graves, Ranking Member Barrow, and members of the Sub-
committee. I am very grateful to be asked to speak to you on dif-
ferent application benefits of genetically modified crops. You have 
described myself tremendously. I appreciate the accolades, and I 
will not go through that on my speech, but I will go ahead and pro-
ceed to the next paragraph. 
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I come before you today speaking as a producer and to speak for 
my producer customers about the benefits of growing genetically 
modified crops, namely, cotton. The general practice of growing 
crops of cotton has dramatically changed in the last 15 years. Since 
I started ginning consulting for the gins in 1988, the customary 
practices of growing cotton have changed in three major ways. 
During the 1988 growing season, it normally took five or six ap-
plications of residual-type herbicide to control weeds in cotton dur-
ing the growing season. We sprayed 10 to 14 applications of worm 
spray to control bollworms, budworms, and armyworms. Then we 
typically sprayed five to six applications of insects for boll weevils. 
The end result was 20 to 25 applications of chemical on a cotton 
field in any given year. Many trips to the field were required, cost-
ing me and my other growers time and money. 
Now we use genetically modified cotton with the Roundup Ready 
and BT genes. Roundup Ready cotton has been genetically en-
hanced to provide herbicide tolerance that allows Roundup herbi-
cide to be applied directly over the top of cotton in the field. Weeds 
that can negatively infect the field are killed while the cotton 
plants live. Because of this technology, Roundup has replaced the 
multiple herbicides I used to use. I also use Bollgard cotton, which 
contains the BT gene to control bollworms and budworms that can 
devastate a cotton crop. 
This year, in contrast to what I did in 1988, I will only apply two 
to three applications of Roundup, a nonresidual herbicide, spray 
two to three times for armyworms, which are not currently con-
trolled by genetically modified cotton varieties suited to my region. 
Because of the success of the boll weevil eradication program, I will 
not have to apply any organophosphates that can be deadly to non-
targeted pests. The result is four to six applications of a pesticide 
on any given field versus the 20 to 25 applications required in 
1988. 
The benefits to me as a grower and to the community as a whole 
are significant. First, I have experienced cost reductions. I have re-
duced total sprays by approximately 15 applications since 1998. 
These chemicals cost approximately $7 per application, and the 
cost of applications covering things like fuel and labor and aerial 
application is $4.15, for a total of $11.15 per acre per application. 
Over the course of 15 applications, that is a savings of approxi-
mately $167 an acre. While growers such as myself have to pay a 
technology fee for biotechnology traits that we use, I calculate that 
my savings are still more than $100 an acre, not to mention re-
duced wear and tear on my equipment and the time I save. 
The biotech cotton varieties I use require a refuge area of 5 per-
cent to ensure that pests do not become resistant to the technology, 
so 95 percent is biotech cotton. Over my 2,500 acres, that means 
I save a total of $237,500. 
This reduced cost is helping my bottom line in an ever-competi-
tive cotton market. Globalization, a new farm bill, Brazil’s WTO 
case, the World Trade Organization case against U.S. cotton pro-
grams and broader World Trade Organization negotiations con-
tinue to bring enormous uncertainties to my future business plan-
ning. But given all of these uncertainties, at least I know that my 
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ability to adopt the latest agricultural technology, such as new 
biotech traits, will help me compete in these changing times. 
Reduced pesticide applications are providing a positive environ-
mental impact. As I mentioned, I have switched from a variety of 
herbicides to using primarily just Roundup on my crops. Unlike 
many other herbicides that I have used in the past, Roundup is 
nonresidual. I have also seen a resurgence in fire ants in my fields 
because I am using fewer broad-spectrum insecticides. While that 
might not seem like a positive impact from biotech crops, it is actu-
ally a good thing for me. You see, fire ants eat eggs from other 
pests in cotton, which means less damage to my crops and even 
fewer pesticide sprays. 
The results on my farm are not unusual. Many other farms in 
the United States and the world have experienced similar positive 
results. A study by the National Center for Food and Agricultural 
Policy found that six biotech crops—corn, canola, cotton, papaya, 
soybeans, and squash—lifted growers’ income by $1.9 billion and 
reduce agricultural chemical use by 46.4 million pounds of active 
ingredients. Additionally, this study found crop yields increased 5.3 
billion pounds. This is money in the pockets of U.S. farmers. 
Even more exciting for me is the prospect of new biotech crops 
yet to come. I traveled to Australia in January 2005 and saw grow-
ers there using Bollgard II on their cotton plants. This technology 
is on the market in the United States but is not currently in very 
many of the varieties that I use. Next season, this technology will 
be available to varieties suited to my region and will be stacked 
with the latest Roundup Ready technology. This new product will 
address the armyworm problem that currently requires two to 
three sprays per season in my area. 
I look forward to utilizing Bollgard II technology in varieties that 
are high yielding, specifically adopted for my growing area, and 
brought to me by U.S. seed companies such as Delta and Pineland 
Seed. This technology will reduce my pesticide sprays even more, 
making more a more efficient and cost-effective grower. 
In closing, I would like to note that we are experiencing ex-
tremely high fuel and fertilizer costs this year, and if it were not 
for genetically modified crops, many farms simply could not be 
profitable. In addition to agricultural biotechnology, I am using 
tools, such as strip till to weed cover crops on 100 percent of my 
acres, verberate soil sampling for fertilizer and lime application to 
most efficiently apply these inputs, aerial imagery to show extreme 
growth and lack of in crops which cannot be detected by the 
ground, and yield monitors to monitor yield variances in the field. 
While you can see that genetically modified crops are not the 
only strategy I use in my farming operation to reduce costs and im-
prove my efficiency and bottom line, biotechnology is a key compo-
nent of my operation. Without biotech cotton, I would have faced 
a tremendous shortfall in my operation. Therefore, continuing to 
encourage the development of new biotech traits for agriculture, 
continuing to seek global acceptance of these crops, and continuing 
to support the rigorous regulatory system that we currently have 
in place to ensure the safety of biotech crops that make their way 
to the market are critical to the success of my operation and of 
American agriculture. 
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As you can see, I do not mind embracing new technologies or 
ideas. The day I do not adopt or try a new technology and ideas 
will be the day I retire. In fact, I think we have only seen the tip 
of the iceberg in agricultural biotechnology. I look forward to future 
products that can make me more efficient or help me address some 
of my most pressing problems, such as a aflatoxins in corn and pea-
nuts and soybeans. I also understand that products that could help 
growers across the United States, such as drought-resistant corn 
and soybeans, are currently being researched. 
I encourage this Committee and Congress as a whole to promote 
new technology and to promote new ideas as we move forward in 
an ever-competitive, global, agricultural environment. Innovation is 
the key to the United States remaining competitive, and we need 
to be sure that we are aware of innovations so that new tech-
nologies continue to flow to farmers such as myself. The future of 
U.S. agriculture’s ability to feed and clothe the world depends on 
it. 
Chairman Graves, Ranking Member Barrows, and members of 
the Subcommittee, thank you again for this opportunity to speak 
on the benefits provided to growers by agricultural biotechnology. 
I look forward to answering any questions you and the Committee 
have. 
[Mr. Dollar’s testimony may be found in the appendix.] 
Mr. GRAVES. Thank you, Mr. Dollar. 
Next, we are going to hear from Mr. Scott Deeter, president and 
CEO of Ventria Bioscience in Sacramento, California. Scott, thanks 
for being here. 
STATEMENT OF SCOTT E. DEETER, VENTRIA BIOSCIENCE 
Mr. DEETER. Good afternoon, Chairman Graves, Mr. Barrow, 
members of the Committee, ladies and gentlemen. It is a pleasure 
to be here. 
My name is Scott Deeter. I am president and CEO of Ventria 
Bioscience, the company that I am representing today in this testi-
mony. I appreciate the opportunity to address the Committee to de-
scribe some of the different applications of genetically modified 
crops. I will briefly describe the company, our technology, and our 
products in development, and I would be happy to answer any 
questions following the testimony. 
First, let me provide an introduction to Ventria Bioscience. 
Ventria was founded with the support and guidance of several lead-
ers in biotechnology and agribusiness who formed the company’s 
board of directors. Our chairman is Tom Urban, who was former 
chairman and CEO of Pioneer Hi-Bred. Other board members in-
clude Bill Rutter and Pablo Valenzuela, who were co-founders of 
Chiron, one of the early biotechnology companies in the U.S.; and 
Hank Rutter, and entrepreneur and attorney by training. Also, Bill 
Crouse is a limited partner of Healthcare Ventures; Dean Hubbard, 
president of Northwest Missouri State; and Mel Booth, who was 
the previous president of Human Genome Sciences and 
MedImmune. 
These industry leaders have committed their resources, their 
time, their talents to realize the vision of improving health care on 
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a global basis utilizing the tools of modern biotechnology combined 
with the industrial might of American agriculture. 
Ventria Bioscience is a plant-made pharmaceutical company. We 
utilize rice and barley as a factory to produce these biologic prod-
ucts. Ventria’s initial products provide human health benefits; how-
ever, the company’s technology has the potential to address many 
challenges faced by other sectors of the economy, including animal 
health, energy, food processing, and industrial processing. 
The company’s core technology is a highly efficient and unsur-
passed method of producing biological products in the seed of self-
pollinating rice and barley. The technology was discovered in col-
laboration with the University of California, as well as other lead-
ing research institutions in the United States. Ventria believes this 
technology will lead to more affordable medicines for a broader pa-
tient population than what is possible today with conventional 
technology. 
Our technological innovation results in a substantial improve-
ment in the economics of biopharmaceutical production. For in-
stance, the capital investment required for Ventria to produce 500 
kilograms of product per year is $4 million. To compare, to produce 
that same amount using conventional technology, such as mamma-
lian cell culture, would cost $125 million, a more than thirtyfold in-
crease. In addition, the operating costs of Ventria’s technology are 
less than one-tenth of conventional technology. 
Now, there are several reasons why this technological and eco-
nomic advantage exists. First, we have been able to achieve ex-
traordinarily high yields of the product in the seed of rice and bar-
ley. 
Second, barley and rice are self-pollinating. They can easily 
achieve the necessary geographic isolation from their food crop 
counterparts to eliminate any concerns of cross-contamination with 
the food supply. 
Third, since processing cost is the primary component of cost of 
goods for biologic products, Ventria’s technology has the advantage 
versus many other systems because it can achieve higher utiliza-
tion rates for the processing facility. That makes the processing fa-
cility much more efficient. The reason for this improvement in effi-
ciency is that these crops can be stored in ambient conditions for 
up to two years without degrading the protein or the biologic in the 
seed. By storing the grain and processing on a continuous basis, 
this allows for high processing capacity utilization and reduced cost 
of goods. 
And, fourth, because rice and barley are safe for human con-
sumption, they are ideal for products that can be delivered orally, 
thereby eliminating the need for expensive separation technology 
that is required by conventional systems to remove infectious or 
toxic contaminants. 
These advantages paved the way for a paradigm shift in bio-
pharmaceutical production for the benefit of patients worldwide. 
As an illustration of the strength of Ventria’s technology, I would 
like to describe some of the human health products in development. 
Ventria’s first two health products are proteins called Lactiva and 
Lysomin. These two proteins are found naturally in mother’s milk, 
saliva, tears, and they contribute to the improved health status 
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that has widely been reported for breast-fed children when com-
pared to their infant formula-fed counterparts. These proteins are 
part of the reason why breast feeding is the best form of nutrition 
for infants and is highly recommended by pediatricians. 
Now, using Ventria’s technology, we can produce these proteins 
cost effectively and incorporate them into a variety of products for 
improved human health. We currently produce Lactiva and 
Lysomin in the seed of rice through contract relationships with se-
lected and well-trained growers. Ventria’s field production is regu-
lated under permits issued by the USDA Animal and Plant Health 
Inspection Service. In fact, last year alone, Ventria’s field location 
was inspected eight times by APHIS inspectors with no compliance 
infractions. Once harvested, the seed is pulverized to a powder and 
transported to a dedicated facility where the final product is proc-
essed into either a concentrate or an isolate. 
The U.S. FDA has regulatory authority over Ventria’s products 
for human health. As part of our premarket activity, we reviewed 
the safety of Lactiva and Lysomin with a panel of scientific and 
medical experts who have unanimously concluded that these prod-
ucts are generally recognized as safe for use in functional and med-
ical foods. The results of the panel review were summarized and 
submitted to FDA where they are currently awaiting clearance 
prior to commercial sale for human health. 
Ventria has several products under development that will incor-
porate Lactiva and Lysomin. One product has been developed for 
children suffering from acute diarrhea. The World Health Organi-
zation estimates 1.9 million children under the age of five die every 
year due to diarrhea. To address this crisis, Ventria added Lactiva 
and Lysomin to an oral rehydration solution, which is a common 
therapy given to children suffering from diarrhea. By adding 
Lactiva and Lysomin, Ventria believes it can improve the recovery 
rate, reduce the severity, as well as the duration of the disease in 
these children. 
This hypothesis is the basis of a recently completed study and 
Peru with 150 children suffering from this disease. Ventria expects 
the results of this study to be published shortly. 
Our production technology enables the cost-effective addition of 
Lactiva and Lysomin to oral-rehydration solution for the benefit of 
millions of children worldwide. 
Ventria is also exploring the use of Lactiva and Lysomin for the 
prevention of diarrhea in the military. During Operation Iraqi 
Freedom, 70 percent of the deployed troops suffered a diarrheal at-
tack, and 43 percent reported decreased job performance as a result 
of this attack. During the Vietnam War, it has been reported that 
hospitalizations due to diarrhea were four times more prevalent 
than malaria. This is a silent enemy attacking American troops. 
Ventria has set its goal to reduce the attack rate by 50 percent 
with the preventive administration of Lactiva and Lysomin. If we 
achieve our objective, it would improve military morale, efficiency, 
and manpower. In terms of manpower productivity alone, this may 
pay for itself due to the cost effectiveness of Ventria’s technology. 
Incidentally, this is a similar problem to that experienced by the 
millions of Americans who travel overseas. 
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Another use of Lactiva that is being developed is for the manage-
ment of inflammatory bowel disease, or IBD. IBD afflicts over one 
million Americans and over four million people worldwide. IBD is 
an extremely debilitating disease that causes severe abdominal 
pain, weight loss, poor absorption of nutrients, and chronic gastro-
intestinal ulcers. Ventria is testing the potential of Lactiva to im-
prove the quality of life for the millions with this disease. 
Ventria is also working with the University of Cincinnati to de-
velop a treatment for chronic lung infections caused by 
Pseudomonas, which is the leading cause of death for patients suf-
fering from cystic fibrosis. Ventria and our collaborators have al-
ready shown successful inhibition of this infection, and we are 
jointly planning a preclinical program to further develop this prod-
uct. 
Recently, Ventria was the recipient of an SBIR grant from the 
National Institutes of Health, National Institute on Aging, related 
to the use of one of Ventria’s products to inhibit biofilms con-
structed by pathogenic bacteria. These types of infections affect 
more than 10 million Americans annually. Infections that are pro-
tected by biofilm are 100 to 1,000 times more resistant to anti-
biotics. So it is important to inhibit the formation of these biofilms 
before they can establish themselves in a wound site. 
Ventria has worked with scientists from the University of Iowa 
and Howard Hughes Medical Institute to develop a natural human 
protein that has been shown to inhibit the ability of pathogens to 
construct these biofilms. Using its plant-made pharmaceutical tech-
nology, Ventria produced and purified the protein and shown the 
effective inhibition. With the SBIR grant, Ventria will further de-
velop this product, with the goal of improving patient recovery by 
reducing the establishment of biofilm infections. 
This concludes my testimony on behalf of Ventria Bioscience to 
describe some of the different applications of genetically modified 
crops. As you can see, combining the tools of biotechnologies with 
the capabilities of modern agriculture, we are able to make a sig-
nificant difference to human health on a global basis. 
I would like to thank Chairman Graves, Mr. Barrow, and Com-
mittee members for your kind attention and the opportunity to tes-
tify. I would be happy to answer any questions following the testi-
mony. 
[Mr. Deeter’s testimony may be found in the appendix.] 
Mr. GRAVES. Thank you, Mr. Deeter. I apologize for the interrup-
tion. Everybody should be happy to know that if we do have an at-
tack in Washington, that our system is working well. 
Next, I am going to turn it over to Mr. Case to introduce our next 
witness. 
Mr. CASE. Thank you, Mr. Chair. Thank you for the courtesy, 
and also thank you for, first of all, highlighting through this forum 
something that is obvious to all of us but not so obvious sometimes 
outside of the Capitol, and that is that small business is agri-
culture, and agriculture is small business; in this country, most of 
agriculture is small business. Also, thank you for the subject mat-
ter of the hearing where I think legitimate concerns are often over-
shadowed by the wrong information and other concerns. 
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I am really happy to introduce Delan ‘‘Rusty’’ Perry from my own 
home state, my constituent. Delan was born and raised on the is-
land of Oahu and graduated from the University of California at 
Berkeley with a degree in political science. He immediately made 
two very good decisions. The first decision was to abandon the po-
litical track and go into agriculture. The second decision was to 
move to my home island, the island of Hawaii, where he went into 
agriculture 30 years ago now, focusing in the very rich, volcanic 
soil of east Hawaii on the island of Hawaii, which, if anybody 
knows that area, is literal a volcanic zone. In fact, where he grows 
papaya and other crops, I actually went down at eight years of age 
from the town of Hilo to watch the volcano erupt in 1960. 
He has owned Kapoho Grown, a diversified ag. farm, for 30 years 
now. He grows a number of different crops as part of the diversified 
agriculture industry of our Hawaii. Papaya is his specialty. Papaya 
is our eighth-largest crop at the moment. By the way, if you want 
to get into some of the history, the four largest crops in Hawaii are 
pine sugar; seed corn, which is clearly intensive in the genetic engi-
neering area; macadamia nuts, all of which have a very heavy com-
ponent. 
He is the past president of the Big Island Farm Bureau. He is 
the president of the Hawaii Papaya Industry Association. He is the 
president also of the Big Island Banana Growers Association. We 
do a little bit of everything there, and I think he has a real story 
to tell about the reality of genetic engineering, and I am looking 
forward to your sharing the story with us. Thank you for being 
here. 
Mr. GRAVES. Mr. Perry, I, too, want to thank you for being here 
and appreciate the fresh papayas that you brought with you. It is 
not something we get in Washington or Missouri very often, and 
I do appreciate that. Very good. 
STATEMENT OF DELAN PERRY, HAWAII PAPAYA INDUSTRY 
ASSOCIATION 
Mr. PERRY. Okay. Thank you very much, Mr. Chairman. Thank 
you, Representative Case, and thank you, members of the Com-
mittee. I am really honored to be here, although it is a little ways 
to come. Aloha and good afternoon. 
My name is Delan Perry. I have been a papaya grower on the 
Big Island since 1974, and I am here today representing the Ha-
waii Papaya Industry Association, which is a state-wide, voluntary 
association of growers, packers, shippers, of which I have been 
president for the last seven years. 
I am always happy to share our experience in commercializing 
virus-resistant papayas. We call it ‘‘The Papaya Story.’’ I am proud 
of the success that we have had using this new technology that was 
brought to our crop. We certainly did not choose to have papaya 
ringspot virus come into our farm and almost put us out of busi-
ness, but we are happy that some visionary scientists recognized 
the potential for this technology in the late 1980’s and that by the 
time this fatal papaya virus came to our major growing area, a 
transformation had been proven to be highly resistant. I also be-
lieve our experience can be useful to other specialty crops, both in 
the United States and throughout the tropics and subtropics. 
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In 1992, as chairman of the Papaya Administrative Committee’s 
Research and Development Subcommittee, it became my job to take 
a research project and find a way to put it into our growers’ hands 
before everyone went out of business. The need of literally several 
hundred pounds of seeds, not hundreds of thousands of pounds of 
seeds, meant that there was really, in reality, little economic incen-
tive for anyone else to do the job. Being farmers, we figured, yeah, 
we can do this. 
The period between 1992, when the virus moved to Puna, which 
is a district on the Big Island, and 1998, when the United States 
deregulation as well as licensing of the relevant intellectual prop-
erties was completed, was a very hard time for my farm, as well 
as hundreds of others of affected papaya growers. Our employees 
went from 17 to one, and I took a job managing an agricultural 
supply co-op for 27 months. I counted the months. We did not plant 
papayas for two years. If the transgenic papaya had not been in the 
works, I would never have gone back to growing papayas. 
One of the things, I think, that differentiates our experience with 
genetically modified crops is that our grower association, at that 
time, the Papaya Administrative Committee, which was a federal 
marketing order, and its successor, Hawaii Papaya Industry Asso-
ciation, with the help of a dedicated group of researchers, took all 
of the steps to bring this elegant solution to a fatal virus to our 
growers through several things: licensing the appropriate intellec-
tual properties; deregulation with USDA, EPA, and FDA; produc-
tion of seed—we got in the seed business; very importantly, dem-
onstrating to both the growers and the wider community the effi-
cacy and the need for the technology; development of a distribution 
plan; development of a marketing plan that had to come; and later, 
deregulating our papayas with Health Canada, so we deregulated 
into Canada, and now we are finishing up the deregulation process 
in Japan, a very important export market. 
Today, almost 60 percent of Hawaii’s papayas have a resistant 
gene in several varieties chosen for their special micro-climates and 
markets. Over 200 growers have received a sublicense from our as-
sociation to grow transgenic varieties. An important issue, segrega-
tion of varieties for the market, and the issue of pollen flow are re-
lated issues and an area that we continue to do research in. We 
believe an important future of our industry is to be able to market 
a variety for every taste. Papaya is also marketed as a whole food, 
which sort of sets it apart from other transgenic crops. It is not 
going to be blended. 
Thus, keeping varieties separate is an important key to market 
expansion. Also, Japan, for instance, has a zero tolerance for non-
deregulated, transgenic products. For these reasons, segregation of 
varieties has become much more important. The Hawaii Papaya In-
dustry Association, together with the Hawaii Department of Agri-
culture, developed and implemented an identity preservation pro-
tocol. Since implementation over two years ago, over 800 acres of 
nontransgenic papayas have been certified, and with careful han-
dling requirements, no transgenic papayas have been shipped to 
Japan. Upon deregulation, we will expect the zero tolerance to be 
relaxed, but we have shown that it is achievable. 
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We have also found that growers, especially inexperienced ones, 
have made mistakes in obtaining seeds or, in the case of organic 
growers, wanted tolerances less than five percent, which is the in-
dustry standard. Since our ongoing research shows that cross-polli-
nation is very limited, I believe that, talking to your neighbor and 
using simple and reasonable practices, all papaya growers will be 
able to grow different varieties side by side without problems. 
We will have the scientific basis to make recommendations before 
long on optimal distances between varieties to ensure varietal in-
tegrity. In fact, most growers already successfully grow two or more 
varieties side by side to support new markets and hedge their virus 
risk. On our farm, we grow three different varieties. 
Papayas are a very important crop throughout the tropics and 
subtropics. Papaya ringspot virus is, likewise, a nasty problem 
most places. Many countries in South America, the Caribbean, Af-
rica, and South and Southeast Asia are working on their own 
transgenic papayas using local scientists, local strains of papaya 
ringspot virus for protection of their local papaya varieties. 
The Hawaii papaya story is told in many places. Just in the last 
few months, we have had visitors from Thailand, the Philippines, 
and Vietnam wanting to see for themselves how well the tech-
nology has worked and what challenges we have overcome. 
Though consumer acceptance has been very good in Hawaii and 
the rest of the U.S. and in Canada, we will have a different chal-
lenge in Japan when deregulation is finished because of the label-
ing requirement. Even though transgenic and non-transgenic pa-
payas are substantially equivalent, I want to acknowledge the 
great help of the Foreign Agricultural Service that has been pro-
viding market research, map and task funds, and much other sup-
port as we approached this challenge. 
Surprisingly, one of the most important consequences of our suc-
cessful commercialization of transgenic papayas has been the at-
tention of the scientific community on papaya research other than 
genetic engineering. It is particularly exciting that the Hawaii Pa-
paya Genome Project will sequence the whole papaya DNA. Some-
time next year, they will be completed. Not only has this sped up 
the answering of regulatory questions on molecular biology, but we 
will soon discover new neutriceuticals hidden in the genome that 
will be the basis for more papaya usage in the future. 
I want to leave you with two thoughts. As a commercial crop for 
domestic and export sales, Hawaii papayas would not have sur-
vived without this technology. And I hope you will agree that our 
papaya can be a model for other small specialty crops which need 
to overcome a similar challenge. I believe we have demonstrated 
this. Papayas are once more a growth industry seeking new pre-
mium markets. 
Thank you for this opportunity to testify on this important issue. 
I will be happy to answer any of your questions. 
[Mr. Perry’s testimony may be found in the appendix.] 
Mr. GRAVES. Thank you, Mr. Perry. 
We will start with questions, and I actually have one for all of 
you, and just to give you a little bit of background on one of the 
reasons why I am so fascinated with this and one of the reasons 
I am so interested in this is this is actually my area. My degree 
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was in plant physiology, and I had every intention after I got out 
of college—obviously, I went back to the farm, and I had every in-
tention of getting a master’s and possibly a doctorate in this field, 
in plant chemistry. Unfortunately or fortunately, however you want 
to look at it, I got sidetracked into politics, and that is where I am 
today. That was not my original track, but it is where I am going, 
and now I have an opportunity to see and help foster some of the 
advancements that are coming at us. 
When I was in school, which was in the early eighties, we were 
just talking about—in fact, Mr. Deeter touched on protieomics and 
breaking it down at the protein level and some of the wonderful op-
portunities of marrying plant science and human science together. 
And, of course, a protein, it does not matter if it comes from a plant 
or a human; it is the same thing. 
But I would be interested in knowing from your respective areas, 
and you are all experts and very knowledgeable in your areas, and 
it does not matter whether it is production outcomes you are look-
ing for or human health outcomes or whatever the case may be; I 
would like to know what you think out there as to what is going 
to knock the public’s socks off, what is one of the wonderful things 
that is going to happen? It may be production, it may be human 
health, but tell me what is fascinating on the horizon today, and, 
Mr. Huttenbauer, we will start with you. 
Mr. HUTTENBAUER. Thank you. From our standpoint, obviously, 
as a plant-made pharmaceutical company, the thing that we hope 
will ultimately knock the public’s socks off is the ability to really 
produce high-quality and low-cost health care. But in particular, 
some of the targeted proteins that we are looking into are proteins 
that cannot be created in the abundance that they are needed to 
be created to address certain health care needs. 
I have one example of approach that we are working on. It is a 
disease that afflicts about 50,000 people worldwide, and because of 
current production constraints, and this is a particular blood pro-
tein, only about 14,000 patients can be treated on a yearly basis. 
In addition to that, the actual costs of those treatments are in ex-
cess of $30,000 per patient. 
So one of the advantages plant-made pharmaceutical has is to 
not only allow for the entire 50,000 patients to be treated but also 
to dramatically lower the cost of the health care. For some people, 
they just simply could not afford it even if it was available, and I 
think that is one of the greatest advantages that we can bring to 
the future. 
Mr. GRAVES. Ms. Parks? 
Ms. PARKS. People, in general, have an extraordinarily personal 
relationship with forests, and they do not realize the number of 
products that actually derive from forests and all of the down-
stream products that come from the manufacturing processes. And 
I think one of the most exciting things that could be available for 
the public is if they could actually maintain that really strong per-
sonal relationship with the forest and have a mechanism to be able 
to produce a lot more wood on a lot less land so they could have 
the products that they want and be able to have the personal expe-
rience with the forest on a regular basis or whenever it is that they 
want that experience. 
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Mr. GRAVES. Mr. Dollar? 
Mr. DOLLAR. One thing you say that would knock the socks off 
of biotech—I am in the rain belt, the southeast United States, but 
we do not get rain when we need it, so we have to have irrigation. 
I have 26 irrigation systems running most of the time when we 
need it. But water issues are becoming bigger and bigger, so if we 
could develop plants that are more water tolerant and do not have 
to have as much water, I think that would be one big item that 
would affect everybody. 
Mr. GRAVES. Mr. Deeter? 
Mr. DEETER. Well, my socks are already off. I am impressed with 
the papaya story. Actually, that, to me, is a major story that really 
is not out there, quite frankly. You do not hear about that in the 
press, that we would not be eating papayas today, but that knocks 
my socks off. 
But I would say that I think there is another item, and that is 
I am reminded when the human insulin gene was cloned, bio-
technology—this was 20 years ago—biotechnology was a scary idea, 
and there was a lot of concern about biopharmaceuticals. But when 
we cloned the human insulin gene and were able to produce insulin 
for diabetics, all of a sudden we had a real product for real patients 
to solve a real, life-threatening problem. And I think that is the 
same for plant-based biotechnology, that as we have a story like 
the papaya industry, something that was saved by biotechnology, 
to me, that is important. But when we also have a mother that can 
stand up and say that my child is alive today because of plant-
made pharmaceuticals, and that I could neither maybe afford that 
product before, or I did not have that product before, to me, that 
is when the public stands up and says that is amazing. 
Now, in order to get there, we have to have a science-based, reg-
ulatory process, and we have to have the research and development 
because, from the data that I am aware of, it takes 10 years to get 
to that point, from the time you start until you actually achieve it. 
So that is what I see as the knock-your-socks-off application in 
plant biotechnology. 
Mr. GRAVES. Mr. Perry? 
Mr. PERRY. Well, I think, from a papaya grower’s standpoint, 
having a papaya in every kitchen would be really great. But look-
ing at the larger picture, I think, in our industry, the thing that 
is most exciting to me is the potential for not necessarily our indus-
try but solving the papaya ringspot virus in places like Bangladesh 
where they really need an easy-to-grow crop full of Vitamin C to 
supplement their diet, and they cannot do it now because they have 
a virus, and this is something that they will be able to commer-
cialize in the foreseeable future. 
And the same thing goes for Thailand where papaya is a very im-
portant fruit. They got ringspot in there, I think, 15 years ago, and 
now it is really hard to grow, and this is the same story you will 
find in a lot of places. In Brazil and Thailand, papaya farmers run 
into virgin forests, chop them down,—you have heard this before—
running away. This is not something that has to be happening in 
the future for papayas anyhow. 
Mr. GRAVES. Thank you. I have got a lot of questions, but I am 
going to let some of the members ask theirs. Mr. Case? 
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Mr. CASE. Thank you very much Mr. Perry. Let me just ask you 
a couple of questions, going back to Hawaii ag., and I would like 
to have a few more questions after you, Mr. Chair, on some other 
aspects. 
You and I both know that in Hawaii we are doing some of the 
most advanced tropical and subtropical agricultural research in the 
world, whether it be the papaya story or other crops, through the 
USDA, which has major facilities in Hawaii, including the Pacific 
Agricultural Research Center right now in Hilo. Can you just out-
line perhaps some of the other applications of genetically engi-
neered solutions in Hawaii, whether it be from a disease-resistance 
perspective or from a crop-yield perspective or, for that matter, the 
cotton water-tolerant analysis? What are the other things that we 
are doing in GE? 
Mr. PERRY. You may know the list better than I do. The ones I 
am familiar with are there is some work on sugar cane. I do not 
know exactly what they are looking for. In pineapple, they are look-
ing for nemintode resistance, which is a serious problem that uti-
lizes a whole lot of chemicals that is accomplishable using genetic 
engineering. Right now, there is some work on orchids, and in that 
area, they are looking at a nice, dark-blue orchid that has a gene 
that is not available in the regular population. The seed corn in-
dustry, as I think you mentioned, is a huge part of our agricultural 
sector now, and there are a number of companies doing a lot of de-
veloping new varieties using our multiseason growing conditions. 
Mr. CASE. And then to go back, just briefly, to the comments you 
were making about the ringspot virus situation, the solution to 
that, as well as these other GE applications, is done in conjunction 
with the federal research facilities, USDA. Could you just talk a lit-
tle bit about the relationship between the private sector and the 
federal government’s agricultural research and scientific facilities? 
Mr. PERRY. Well, we have been working with various research, 
USDA research, in the past. I think the ground breaking just last 
week for the facility in Hilo is a great opportunity to house every-
body together in potentially a large facility serving not only Hawaii 
but the whole Pacific Basin. The director, Dennis Gonsalves, is the 
person that actually made the cassette that was inserted into the 
papaya back in Cornell in the eighties. He is one of these visionary 
scientists that I was talking about. We maintain a continuing, real-
ly good relationship with them. They have helped us out enor-
mously in coming up with the microbiological research to finish our 
deregulation process in Japan. 
Mr. CASE. Just so I can be clear on deregulation, ‘‘deregulation’’ 
refers to the fact that they are going to let the product in and allow 
it to be marketed. Right? Is that essentially what that is? 
Mr. PERRY. Well, you know, if you ask them, they say it is a safe-
ty review. We say it is deregulation, but that is what it is. Every 
country has their own set of rules that you have to go through, 
and, in some cases, they require extra research, things that we did 
not have to do for FDA, looking at different aspects, and that is 
what we think we have completed in Japan. So getting all of the 
safety information or data that they think is necessary to say, 
yeah, this something we want our people to eat. 
Mr. CASE. Thank you. 
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Mr. GRAVES. Mr. Sodrel? 
Mr. SODREL. I heard a little bit earlier about the crop separation 
and making sure the genetically engineered crops did not get mixed 
in with other crops. What is the worst-case scenario, if they do get 
mixed together? 
Mr. HUTTENBAUER. To properly answer that question, I would 
have to say it would depend somewhat on what the actual output 
product is that is being engineered. The worst-case scenario in the 
two targeted outputs that we are going after would be that an or-
ganic flax farmer, for instance, would not be able to indicate that 
they actually had organic crops. The actual molecules themselves 
are completely harmless if ingested, so that would not be an issue 
in terms of contamination. 
I think it is interesting that even though there have been some 
instances of crop contamination that have been highly publicized, 
and I referred earlier to the Starlink corn, there has not been a sin-
gle case of anyone being harmed from a genetically modified crop 
in the entire history that they have been developed. I think regula-
tions are in existence that are doing a pretty good job of keeping 
that from happening. I think they are advancing. 
As technology advances, things such as gene containment can 
further advance that crop separation, but I cannot say that there 
is not something that is being devised right now in a plant that if 
it did get into a food system could not be harmful, but that is also 
why the systems for containment exist. 
Mr. SODREL. So it is fair to say it is more a perception problem 
than it is a reality problem. 
Mr. HUTTENBAUER. I would say greatly so. In my experience, the 
Starlink corn gets brought up time and time again, and, you know, 
it was an unfortunate incident, and one of the problems perhaps 
with corn, because of the pollen transfer, and also the folks from 
Ventria mentioned that the use of self-pollinating crops is one way 
to mitigate that containment issue, as we go forward there are lots 
of new ways to do this well. But I would say, largely, it is a self-
perception issue versus the reality of the dangers there. 
Mr. SODREL. Thank you, Mr. Chairman. 
Mr. GRAVES. Thank you, Mr. Sodrel. 
My next question is probably for Mr. Deeter and Mr. 
Huttenbauer. Can you talk a little bit about how your technologies 
might be used in other areas of agriculture, animal agriculture, for 
instance? Go ahead, Mr. Deeter. 
Mr. DEETER. Sure. In fact, that is an interesting question be-
cause Ventria has been looking at the opportunity to replace anti-
biotics that are used in production agriculture today with a natural 
and a microbial protein that could be produced in the seed of bar-
ley, for instance. These could essentially eliminate the need for 
antibiotics in confined animal feeding operations. 
Now, today, antibiotics are used broadly, of course, because they 
not only promote growth, but they also keep at bay the pathogenic 
infections that can be devastating for a confined animal feeding 
program. But if we could deliver in the barley, ground, pulverized 
powder, say, of barley that contains an antimicrobial protein and 
eliminate the need for the antibiotic, that would be significant not 
only for animal health, but there is a significant impact to human 
VerDate 0ct 09 2002 13:37 Nov 15, 2005 Jkt 000000 PO 00000 Frm 00028 Fmt 6633 Sfmt 6633 G:\HEARINGS\23179.TXT MIKE
25
health because these same antibiotics that are used in animal pro-
duction agriculture can potentially cause resistance to develop in 
the human population and make the antibiotics that we use for 
human health less effective. 
So if we can eliminate pathogenic infections and do that without 
a loss of the benefits of antibiotics, that would be significant. 
Mr. HUTTENBAUER. Along with animal antibiotics, one of the 
things that we have been looking at in terms of the effects on ani-
mals is essentially enhancing animals’ health effects on humans 
consuming them. One of the things that we have undertaken is a 
study of cattle being fed using DHA-enhanced flax in a feed pro-
gram which ultimately translates the health benefits of the Omega 
3’s into the cattle so that humans downstream consuming them 
could take advantage of those healthy benefits which currently are 
basically limited to fish or fish oil supplements. As well, we have 
looked at programs involving chicken feed and the healthy benefits 
being imparted on the eggs as well, again, really around Omega 3. 
So that is one avenue in terms of animal health that could be ap-
plied with this. 
Mr. GRAVES. I am curious, real quick, Mr. Perry. You mentioned 
possible markets,—Europe, China, Korea—and Europe has tradi-
tionally resisted GMOs considerably, and it has been a little bit of 
an education process, but we are still not there yet. I know you are 
look at those as potential markets. Do you have any ideas on how 
you are going to combat that or work through that or what you are 
going to do to try to get them to overcome their fears, you might 
say? 
Mr. PERRY. Well, to start with, one of the things that we have 
relied on is voluntary researchers, and that has slowed the process 
down a little bit, and for that reason, we are chewing these deregu-
lation issues off country by country, one by one, and after we finish 
Japan, we do sell papayas to the EU. I think this is something that 
we believe we will have all of the basic research that they will ask 
for, and the same would be true of China and Korea. 
The future for us is looking at premium markets. We cannot 
compete with some of the South American countries for price be-
cause of our costs, but we can look at premium markets, and these, 
because it is so difficult to grow nonvirus-resistant papayas, these 
are things that the countries are going to have to look at, going 
through the same deregulatory process. 
Mr. GRAVES. Mr. Case, did you have a follow-up? If you have got 
a follow-up, go ahead, Mr. Sodrel. 
Mr. SODREL. I just have a question. Ms. Parks, in my district, 
about 20,000 people make their living out of forest products, so 
trees are of great interest. The ash borer in Central Park in New 
York; they have got smoke jumpers crawling up the trees trying to 
find the trees that are infected. 
You talked a lot about growing the trees faster and the makeup 
of the tree, the pulp content and so on. Can we also look for dis-
ease-resistant or insect-resistant trees as well? 
Ms. PARKS. Absolutely. ArborGen is currently not working on dis-
ease or pest resistance because we are working with more commer-
cial species in the southern United States and in Brazil, but there 
are quite a few universities who are actually looking at different 
VerDate 0ct 09 2002 13:37 Nov 15, 2005 Jkt 000000 PO 00000 Frm 00029 Fmt 6633 Sfmt 6633 G:\HEARINGS\23179.TXT MIKE
26
ways to manage pest and disease resistance, and, in fact, Syracuse 
University and the State University of New York are also looking 
at how can they expand their programs to try to address some of 
those issues as well. 
Mr. GRAVES. Mr. Case? 
Mr. CASE. Thank you. Since we are in the Small Business Com-
mittee, let me ask you some questions related to federal programs 
available to small business. I have a suspicion that I have never 
actually checked out—perhaps it is just more anecdotal—that agri-
culture small businesses may tend to access our federal govern-
ment programs at a lower rate than perhaps other kinds of small 
businesses, technology or whatever else. 
I do not know if it is true or not; it just occurs to me that it 
might be true, and I am not talking about USDA scientific because 
I think agriculture has been able to access that just fine, at least 
from my perspective. But I am talking about things like the EDA 
and the SBA and USDA rural development. Have each one of your 
companies utilized those programs of the federal government in the 
small business area for venture capital, start-up loans, basic ad-
vice, and how is it going from that perspective? I will just go right 
down the list. If you could just briefly give me a quick picture. 
Mr. HUTTENBAUER. From our standpoint, we have not utilized 
them, and the reasons were twofold. One was, as I think you al-
luded to, the relatively small size of the potential contribution, and, 
secondly, because we are dealing in biotech, and there is a degree 
of secrecy in what we are doing, the initial thoughts were to main-
tain some of the secrets, if you will, of what we were developing, 
so we chose not to go that route for initial funding. 
Ms. PARKS. We have only just begun exploring some of those pro-
grams. In the first place, we started this with the SBIR and discov-
ered that, at this point in time, those funds are not available to us. 
But forestry in general and forest biotechnology is very under-
funded at this point in time, so we are trying to look at a lot of 
different options that we could approach the government for fund-
ing. 
Mr. DOLLAR. We currently do not use anything. We have looked 
at some SBA loans when we have had some hurricanes come 
through, and we were ineligible for those SBA loans. When we did 
start the first cotton gin in 1988, we used FHA business and indus-
try loans, and other than about eight inches’ worth of paperwork, 
they were very helpful for our gin because there had not been a gin 
in our county since 1922. So our bankers were a little reluctant to 
put a gin in without a little back-up help, so we were able to secure 
a business and industry loan from FHA in ’88. 
Mr. DEETER. We have received recently an SBIR grant, Phase I, 
for $100,000, which is really our first foray into a collaborative pro-
gram with the federal government, but that is something that we 
believe, especially with the case of the prevention of military diar-
rhea, that is obviously something for benefit for DARPA, so we will 
explore that opportunity. We will also explore other SBIRs. I think 
that is something that we have not done a lot of. We are only 15 
employees today, but it is something that we would really like to 
do going forward. 
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I must say, it does take some time. It takes the time of some of 
your best people, and the process to receive that type of funding is 
fairly significant. I think the first phase is $100,000. Of course, it 
can be larger than that going down the road. To put that in per-
spective, to date, our investors, which are all individuals, have in-
vested $35 million in Ventria to get us to where we are. So 
$100,000 out of $35 million is the share. 
Mr. PERRY. Well, I think I mentioned earlier that we have a very 
good relationship with the Foreign Agricultural Service, and we 
have utilized their programs for our papaya administrative Com-
mittee before and now the Hawaii Papaya Industry Association. 
Two years ago, we got a task grant to help us complete some of the 
research for our Japan deregulation 
Mr. CASE. Thank you. Very helpful. 
Mr. GRAVES. Dovetailing on talking about the small business as-
pects, and I do want to change gears just a little bit, and this may 
be more for Ventria and Agragen, but as far as developing your 
technology, growing your technology, you might talk a little bit 
about the aspects of utilizing farmers, contracting with farmers to 
do that. Are you planning on doing that yourself? You just might 
explain what is happening there. Mr. Dollar, you may have some 
experience with that, too, but go ahead. 
Mr. DEETER. Actually, our technology, we use today contract 
growers that grow, and these are growers that have been certified, 
trained growers. They are monitored. There is quite an auditing 
process and inspection process. We will expand that grower base as 
the company grows and as our products develop and commercialize. 
Our first two products, Lactiva and Lysomin, represent tens of 
thousands of acres, so it is not millions of acres initially, but it is 
a start. We seek growers that have the skills and capabilities, and 
most importantly, the desire to learn the skills and capabilities for 
our type of production because this is a very different type of pro-
duction than commodity food production, a totally separated, to-
tally dedicated type of production with new skills, new capabilities. 
What is the payoff? We expect these growers will make double 
what they could make with their best alternative commodity pro-
duction, so they will make two times what they can make with 
their next best alternative. They will not only make more money, 
but they will be trained in new areas, and those skills and capabili-
ties will also, we believe, have value down the road. 
To put this in perspective, once we are fully commercialized, we 
expect the first two products that we are developing to increase, 
and this is an increase over what they could make in their best al-
ternative—it will increase their income by $10 million every year. 
Now, this is, again, tens of thousands acres; it is not millions of 
acres. It will be very significant for those growers who elect to par-
ticipate, but, again, our first products will not be millions of acres. 
That is really not our plan. 
I want to also mention, the amount of federal crop subsidies that 
Ventria receives is zero. These crops are not subsidized at all, so 
it is a 100-percent benefit to the grower. 
Mr. GRAVES. That is a good point. 
Mr. HUTTENBAUER. I think a lot of what we are doing is mirrored 
with Scott’s commentary, and I should also point out that they are 
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further down the road than we are. We are looking at also going 
with the contract grower system. We have commitments now for 
roughly the first 16,000 acres when we get to the stage when we 
are actually planting. Again, the importance of establishing a con-
tract grower system, because of the closed-loop network of how this 
has to be contained and the regulatory environment, it is almost 
essential to have a preestablished network of farmers. 
As I pointed out in our testimony, we are truly looking at large-
scale agriculture. The first two components that we are going to be 
making are upwards in the neighborhood of 100,000 acres, so the 
potential for a rather large contract grower network exists. 
As PMPs advance, I can certainly see a lot of the learning that 
is derived from some of these initial companies being passed down 
and farmers forming actual PMP growing networks, if you will, 
going forward that are established exclusively for PMPs because 
there will be some isolation to that, and you could get to the stage 
where a certain portion of a state may be set aside for specific PMP 
farming. 
Mr. GRAVES. In agriculture, as profit margins get squeezed nar-
rower all of the time, and that is happening all of the time, you 
know, we are obviously looking for more opportunities to make ag-
riculture work. Unfortunately, we are price takers on both sides. 
We do it a little bit different than other industries. We buy every-
thing retail and sell everything wholesale, so we are price takers 
at both ends, and we have to find opportunities, and I think these 
are wonderful opportunities to be looking at. Mr. Case, do you have 
any more? 
Mr. CASE. Just a quick question. The federal government obvi-
ously regulates genetically engineered crops through a tripartite 
regulation structure. Last year, the secretary of agriculture opened 
up a docket to take comments on the potential revision of those 
regulations. Did any of you participate or make submissions on 
that docket or, through your trade industries, make any rec-
ommendations, and what were they if you did it? 
Mr. DEETER. We have been involved through the Biotechnology 
Industry Organization. First of all, as, I think, the history of man-
kind shows, when technologies like plant biotechnology first enter 
the public domain, there is often a violent and very emotional reac-
tion, and it has been true for biotechnology in general, not only 
plant biotechnology but biotechnology in general. I would say, 
thanks to a scientifically driven, regulatory process, we have al-
lowed the differences of opinion to surface. We have been able to 
consider the scientific facts, and we are not swayed as much by the 
emotional arguments that are really meant to stymie the innovator 
and arrest progress in these important areas. 
I think that we have got to keep steadfast in the science-driven 
regulatory process, and with BIO’s help,—Ventria is a small com-
pany, and we do not have a team that can spend a lot of time work-
ing with new types of regulations, so we work mostly through 
BIO—we have been able to improve upon the base of regulatory 
structure. We have been working with new regulations related to 
advantageous presence so that it is more of a scientifically sound 
approach. 
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The member asked the question, what would happen if there was 
a contamination? Well, I cannot speak for every product, but I can 
speak for Ventria’s products. You know, it is in mother’s milk. 
These proteins are in saliva. They are in our tears. What would 
happen? You might be healthier. 
So I think we need to remove the emotion, focus on the scientif-
ically driven, regulatory process and do not put in regulations that 
serve no other purpose if there is really no scientifically valid rea-
son for it. 
Ms. PARKS. ArborGen participated on behalf of ArborGen and as 
part of BIO and as part of a coalition that was developed for peren-
nial and specialty crops, and our position had been, when we spoke 
with APHIS, is that the current regulations obviously demonstrate 
that there is a lot of safety in the way the regulations are currently 
enforced and that any new regulations should still continue to be 
developed so that decisions are made on a case-by-case basis based 
on the product, the trait, species of interest, and that APHIS 
should have the opportunity to streamline processes where the biol-
ogy of the plant is well understood and where the application of the 
plant in the field is well understood. 
And so we have, in our conversations with APHIS, just strongly 
encouraged them not to create any kind of overburdensome regula-
tions based on a particular type of plant or the nature of the plant 
as in a perennial crop simply because they are gaining experience 
with how that product or that crop works because the system to 
date has worked very well, and we would fully like to have our 
products go in under the current system or with modifications 
made for the specific trait or species of interest that we have. 
Mr. GRAVES. Mr. Barrow? 
Mr. BARROW. Thank you, Mr. Chairman. I apologize for my ab-
sence, but my other Committee is meeting and marking up a bill 
today, and so I had to be running back and forth, and I appreciate 
your indulgence and that of the witnesses. 
I would like to ask Mr. Dollar a couple of questions, if I can, that 
are matters that I do not think have been covered. First of all, I 
will preface this by saying, I am sure that the farmers here who 
farm for a living and some of the old hands on this Committee do 
not need an education in all of this stuff, but I am fascinated to 
learn the impact that biotechnology is having in such matters as 
fighting weeds in crop production. 
So, Mr. Dollar, for those of us who are not all that well versed, 
either by background or experience, could you help us have a better 
understanding of just exactly what biotechnology is helping you all 
do and making it easier for you all to manage crop production deal-
ing with weeds? 
Mr. DOLLAR. Well, before Roundup Ready crops, we used several 
different methods, most of them called Blue Steel, which you had 
to have a good tractor operator and a good piece of equipment, and 
you would plow the fields, but you could not get all of the crops. 
Then with the advent of 24D’s and atrizenes, we had not hard 
chemicals, so to speak, but chemicals that left a residual, and they 
would show up a couple of weeks later or may interfere with a crop 
that is planted in a rotation behind the crop that you are planting 
at a certain time. 
VerDate 0ct 09 2002 13:37 Nov 15, 2005 Jkt 000000 PO 00000 Frm 00033 Fmt 6633 Sfmt 6633 G:\HEARINGS\23179.TXT MIKE
30
So with the advent of Roundup Ready crops, we do not have any 
residual left over, so we can plant a vegetable crop. In south Geor-
gia, we are 20 miles from the Florida line, so we will have sweet 
corn following cotton, or we will have snap beans following cotton, 
or we will have peanuts following cotton. So with the advent of 
those crops following the crops that we are growing, we do not 
want to put a harsh or long-residual chemical out there that may 
show up in a nontarget crop. 
So the Roundup has been efficient for that for us, and also some-
times you would have to spray a multitude of chemicals to kill a 
grass, to kill a broad leaf, certain types of monocot plants or dicot 
plants, you would have to use several different herbicides, and 
those would be very cost prohibitive on a low-input crop like soy-
beans or field corn, and Roundup has leveled the playing field, so 
to speak. 
Mr. BARROW. In some of the testimony we heard earlier today, 
folks were talking about trying to segregate or keep new, innova-
tive crops and products of biotechnology away from the larger pop-
ulation for a variety of reasons. That brought to mind something 
I wanted to discuss with you, and that is how are you in the indus-
try, how are farmers and the folks who are supplying you all with 
biotechnology, how are you all responding to the concerns that folks 
have about growing a generation, if you will, of pests that have in-
creased tolerance for the things we are engineering into the plants 
to make them resistant to the pests? What are you all doing to deal 
with that because I know that is a concern on the part of folks gen-
erally? 
Mr. DOLLAR. Well, in cotton, the crops, what we will do is we will 
have a 20-percent rule or a 5-percent rule that when we are plant-
ing a non-BT or non-Roundup Ready crop that we will basically let 
that crop go to waste so that, say, on BT cotton, we will not spray 
it with any type of chemicals so it will host a generation of pests 
or insects that may be tolerant at one time or another to BT, but 
then it will decrease its vulnerability to be more tolerant over the 
long term. 
Monsanto, which developed a lot of this technology, along with 
the EPA, mandate what we do as farmers and how much land we 
leave out and plant to a host crop so we will not have a problem 
later on down the line. We are very keenly aware of how beneficial 
this crop has been to us from the advent, so we, as farmers, adhere 
to those rules, the 100 percent, and Monsanto is also developing 
some crops. Bollgard II, that was a new type of crop that will work 
better on armyworm complex, and then eventually they will phase 
out the Bollgard I altogether so we will not build up any resistance. 
Mr. BARROW. It sounds to me like what you are saying is you will 
sacrifice, you will, by design and by practice, by good management 
practice, sacrifice a percentage of your crop for the greater good of 
making sure that you do not evolve or grow a whole generation of 
pests that will be able to overcome that engineering. 
Mr. DOLLAR. Correct. 
Mr. BARROW. Two questions as a follow-up to that. One, are you 
still able to make more? Does the increase in productivity, despite 
that sacrifice, still make it a good deal for you all? And, secondly, 
is this something you all are just doing on the buddy system, on 
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the honor system, or is this something that is mandated and actu-
ally policed to make sure that these best-management practices are 
actually followed? 
Mr. DOLLAR. It is mandated by EPA, and then Monsanto and— 
[Loudspeaker announcement.] 
Mr. BARROW. To return to my question, the concern I had was 
that while it is a good idea for everybody to do that in order to 
make sure that you do not grow up a generation of pests that have 
an increased tolerance of this, how are they making sure that ev-
erybody is doing that so that nobody is going to opt out of that sys-
tem in order to get that extra 5 or 20 percent of capacity out of 
their crop ? 
Mr. DOLLAR. Monsanto and EPA; we have spot checks. They will 
come by and check fields randomly for the BT gene in the cotton 
plant. Probably the biggest policing person we have is your neigh-
bor because your neighbor does not want you to get an edge up on 
him. So I think there has been more farmer-to-farmer tattle telling 
when there have been instances or occasions than the greater good 
that Monsanto or EPA can do because everybody wants to be treat-
ed the same, and everybody wants to make sure they get treated 
the same. 
Mr. BARROW. I understand. I appreciate that. And, finally, some-
thing you touched on in your testimony earlier, I want to return 
to, and that is the subject of what some folks refer to as the tech-
nology fees, the research and development costs, that are passed 
along for the products of biotechnology. Can you give us your as-
sessment of whether or not they are reasonable in light of the ben-
efits? 
Mr. DOLLAR. Well, in light of the testimony of the people to my 
right and the people to my left in talking about funding from other 
sources to try to develop this, developing technology is a very ex-
pensive way to make a living, and with that in mind, the tech-
nology that we pay as farmers is always too much. Anything we 
have got as farmers is too much fee, but with the farmers in mind 
and the amount of money that we spent prior to the 1988 or prior 
to 1995, when we started going to Roundup Ready and BT crops, 
it is a value. There is a lot of value. We are saving $167 an acre, 
and our technology fee is not even a third of that. 
It is grumbling when you look at your end of the year, your P&L, 
and you say, I paid X number of dollars to a technology fee, and 
that bothers you. It is like you look at the end of the year, and you 
see how much money you spent on groceries or anything else, and 
when you itemize it up, you say it is a lot of money, but if you 
turned around and itemized how many bills you would have had 
spraying all of these different chemicals and all of these application 
costs, you do not have that to look at now, so you tend to forget 
about it, and you tend to complain. 
Mr. BARROW. Thank you, Mr. Dollar. 
Mr. DOLLAR. Thank you. 
Mr. GRAVES. I apologize for the interruption again. Stay away 
from the Hart Building and welcome to post-9/11 Washington, 
D.C., unfortunately. Sometimes we have those a lot; sometimes we 
do not. Unfortunately, that is part of the process today. 
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I want to thank all of the witnesses for being here again. All of 
the statements made by members and the witnesses will be in-
cluded in the record in their entirety. I do appreciate some of you 
came a long ways to be here, and I do appreciate it. 
I want to introduce one individual who is here, State Senator 
David Clint from Missouri, who is a leader in biotechnology as both 
a producer and as a member of the state Senate in Missouri. I am 
very pleased that he came out here to hear this hearing. David, 
thank you for being here. 
I also want to make sure everybody knows we are having a re-
ception in this hearing room at 5 o’clock for all of the witnesses 
who are here, if you can stick around, and for the audience to 
know, too, if you can stick around, please come back and attend 
that. It will be right here in this hearing room on the balcony, if 
you can make it. I hope you will be here. 
Thank you all for coming, and I appreciate it very much. Very 
enlightening. This is cutting-edge technology, and it fascinates me, 
and I am looking forward to moving forward with it. Thank you. 
[Whereupon, at 3:49 p.m., the Subcommittee was adjourned.]
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